Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityOther Non-Current LiabilitiesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Goldenwell Biotech (GWLL) Liabilities and Shareholders Equity (2019 - 2025)

Goldenwell Biotech filings provide 7 years of Liabilities and Shareholders Equity readings, the most recent being $220410.0 for Q3 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 22.84% to $220410.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $887812.0, a 10.03% increase, with the full-year FY2024 number at $224192.0, down 1.71% from a year prior.
  • Liabilities and Shareholders Equity hit $220410.0 in Q3 2025 for Goldenwell Biotech, down from $251295.0 in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $509176.0 in Q2 2021 to a low of $179432.0 in Q3 2024.
  • Median Liabilities and Shareholders Equity over the past 5 years was $228094.0 (2023), compared with a mean of $278007.5.
  • Biggest five-year swings in Liabilities and Shareholders Equity: skyrocketed 93.92% in 2021 and later tumbled 46.11% in 2022.
  • Goldenwell Biotech's Liabilities and Shareholders Equity stood at $460979.0 in 2021, then tumbled by 46.11% to $248400.0 in 2022, then dropped by 8.17% to $228094.0 in 2023, then decreased by 1.71% to $224192.0 in 2024, then dropped by 1.69% to $220410.0 in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $220410.0 (Q3 2025), $251295.0 (Q2 2025), and $191915.0 (Q1 2025) per Business Quant data.